ODC1

Ornithine decarboxylase · P11926 · ODC1 on Sugi Atlas →

3,234 patent compounds predicted against ODC1, 1,961 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8567021	0.49	4/20
SCHEMBL969511	0.42	4/20
Lupinifolin (SCHEMBL6207285)	0.67	3/20
Minimiflorin (SCHEMBL5461834)	0.60	3/20
Lupinifolinol (SCHEMBL6668491)	0.49	3/20
Chromene (SCHEMBL6271733)	0.47	3/20
SCHEMBL3705603	0.46	3/20
Eflornithine (SCHEMBL26327)	1.00	2/20
Eflornithine, (S)- (SCHEMBL60698)	1.00	2/20
D-Eflornithine (SCHEMBL60699)	1.00	2/20
SCHEMBL996766	1.00	2/20
SCHEMBL3831414	1.00	2/20
SCHEMBL3831417	1.00	2/20
Eflornithine (SCHEMBL8581344)	1.00	2/20
Eflornithine, (S)- (SCHEMBL1322403)	0.96	2/20
Eflornithine (SCHEMBL3022583)	0.96	2/20
Eflornithine (SCHEMBL3244711)	0.96	2/20
Eflornithine, (S)- (SCHEMBL3244714)	0.96	2/20
D-Eflornithine (SCHEMBL3244719)	0.96	2/20
Eflornithine (SCHEMBL6779168)	0.96	2/20

Clinical trials — most relevant to ODC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
L-ornithine L-aspartate in Overt Hepatic Encephalopathy	PHASE4	COMPLETED
L-arginine Treatment in Mild Hypertension	PHASE4	UNKNOWN
N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia	PHASE2/PHASE3	UNKNOWN
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes	PHASE3	NOT_YET_RECRUITING
A Phase I/II Open-label Safety and Efficacy Study of LNP.UCD.ABE in Patients With Urea Cycle Disorders.	PHASE1/PHASE2	NOT_YET_RECRUITING
Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency	PHASE1/PHASE2	WITHDRAWN
Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency	PHASE1/PHASE2	COMPLETED
Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn	PHASE1/PHASE2	RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial	PHASE2	COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors	PHASE1	COMPLETED
Valproic Acid in Childhood Progressive Brain Tumors	PHASE1	WITHDRAWN
Prevalence of DAO (diamino Oxidase) Deficiency in Newborns	nan	COMPLETED
Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients	nan	COMPLETED
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD	nan	UNKNOWN
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD	nan	COMPLETED
Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding	nan	WITHDRAWN
Neurologic Injuries in Adults With Urea Cycle Disorders	nan	COMPLETED
Primary Hyperoxaluria Mutation Genotyping/Phenotyping	nan	COMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease	nan	RECRUITING
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions	nan	RECRUITING
Gyrate Atrophy Ocular and Systemic Study	nan	ACTIVE_NOT_RECRUITING
Clinical and Laboratory Study of Methylmalonic Acidemia	nan	RECRUITING
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients.	nan	COMPLETED
Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Diabetes	nan	UNKNOWN
Multi-omics Study in Citrin Deficiency	nan	ACTIVE_NOT_RECRUITING
Genetic Variants and Regulation of Specialized Pro-resolving Mediator	nan	RECRUITING
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ODC1 binder may also engage these)

Protein	Name	Similarity
P27119	—	1.000	P27119 →
P27117	—	1.000	P27117 →
P27118	—	1.000	P27118 →
P27120	—	0.995	P27120 →
P09057	—	0.994	P09057 →
P00860	—	0.994	P00860 →
Q9I8S4	—	0.983	Q9I8S4 →
P14019	—	0.981	P14019 →
Q8R2J9	—	0.948	Q8R2J9 →
Q9WU65	—	0.947	Q9WU65 →
O43502	—	0.947	O43502 →
Q4R4D5	—	0.945	Q4R4D5 →
Q8N0X4	—	0.943	Q8N0X4 →
Q8R4N0	—	0.943	Q8R4N0 →
Q924H5	—	0.942	Q924H5 →
E0CSI1	—	0.942	E0CSI1 →
O23653	—	0.941	O23653 →
Q9D020	—	0.941	Q9D020 →
Q811P6	—	0.941	Q811P6 →
Q6DKB0	—	0.941	Q6DKB0 →
B9N1F9	—	0.940	B9N1F9 →
Q9M8Z7	—	0.940	Q9M8Z7 →
Q5I0K3	—	0.940	Q5I0K3 →
E1C6Q1	—	0.940	E1C6Q1 →
Q91WC3	—	0.939	Q91WC3 →
Q96A70	—	0.939	Q96A70 →
Q9H0P0	—	0.939	Q9H0P0 →
Q8WVM0	—	0.939	Q8WVM0 →
Q9FL12	—	0.938	Q9FL12 →
Q14410	—	0.938	Q14410 →